ProfileGDS5678 / 1457276_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 56% 56% 58% 58% 60% 53% 55% 55% 56% 55% 56% 55% 50% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4606656
GSM967853U87-EV human glioblastoma xenograft - Control 23.4069756
GSM967854U87-EV human glioblastoma xenograft - Control 33.4092656
GSM967855U87-EV human glioblastoma xenograft - Control 43.4337758
GSM967856U87-EV human glioblastoma xenograft - Control 53.4518158
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6726560
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.393753
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3814455
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3701155
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3938256
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3802855
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3762456
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3987955
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1889950